Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

European Phase III clinical trial of budesonide MMX completes patient enrollment

Santarus, Inc., a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX: COPN), has completed enrollment of 514 patients in the European Phase III clinical trial to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis.

3 Dec 2009

Research finds change in the outlook of people with type 2 diabetes and heart disease

The outlook for individuals with type 2 diabetes and coronary artery disease is not as grim as originally believed, according to new Saint Louis University research published in Circulation, the Journal of the American Heart Association.

2 Dec 2009

Roche announces results of phase III taspoglutide study in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche.

2 Dec 2009

FDA approves Schering-Plough's New Drug Application for ZEGERID OTC capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Schering-Plough HealthCare Products, Inc.’s, New Drug Application (NDA) for ZEGERID OTC™ Capsules (omeprazole/sodium bicarbonate) with a dosage strength of 20 mg of omeprazole for over-the-counter (OTC) treatment of frequent heartburn.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

LeapFrog Investments announces ZAR 50 million investment in AllLife

LeapFrog Investments has announced a ZAR 50 million (over US$6 million) investment in AllLife, the innovative South African insurer serving people living with HIV and diabetes.

2 Dec 2009

D-ATLAS to map the prevalence and costs associated with type 2 diabetes launched

Pinpointing the prevalence and cost of type 2 diabetes and now, the prevalence of obesity (Body Mass Index [BMI] of 30 or greater), is just a mouse click away thanks to a Web-based tool developed by the National Minority Quality Forum (NMQF).

1 Dec 2009

Type 1 diabetes youth have abnormal insulin resistance that may increase risk of cardiovascular disease

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), youth with type 1 diabetes have now been found to have abnormal insulin resistance. Having abnormal insulin resistance appears to negatively affect heart, blood vessel and exercise function in this population.

1 Dec 2009

Women with gestational glucose intolerance at risk of metabolic syndrome

Women who have gestational glucose intolerance (a condition less severe than gestational diabetes) exhibit multiple cardiovascular risk factors as early as three months after birth, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

1 Dec 2009

Drinking sugar-sweetened cola a week prior to pregnancy elevates diabetes during pregnancy

Researchers from LSU Health Sciences Center New Orleans School of Public Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Harvard School of Public Health, Brigham and Women's Hospital, and Harvard Medical School, have found for the first time that drinking more than 5 servings of sugar- sweetened cola a week prior to pregnancy appears to significantly elevate the risk of developing diabetes during pregnancy.

1 Dec 2009

European Commission approves MICARDIS medication for CV protection

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

27 Nov 2009

Researchers predict diabetes cases to double and cost to triple in the next 25 years

The diabetes population in the United States will almost double over the next 25 years and annual medical spending on the disease is projected to hit $336 billion, up from $113 billion today, according to a study published in the December issue of Diabetes Care. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis by a team from the University of Chicago.

27 Nov 2009

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.

27 Nov 2009

Experts say vitamin D assists body's immune system to fight against H1N1

The world's leading vitamin D experts say that raising your levels of "the sunshine vitamin" this winter might be the best way to help your body naturally raise its resistance to all forms of the flu virus - including the H1N1 swine flu virus.

26 Nov 2009

Aetna Better Health teams up with Hartford student to highlight the importance of diabetes and health literacy

For the second time this year, Aetna Better Health in Connecticut is teaming up with a local student to help complete a senior year “Social Justice Project,” while at the same time informing local residents on the important issues of diabetes and health literacy.

26 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

Many people who are overweight or obese develop insulin resistance and type 2 diabetes at some stage in their lives. A European research team has now discovered that obese people have large amounts of the molecule CXCL5, produced by certain cells in fatty tissue.

25 Nov 2009

DSS sets evidence-based guidelines and definitions to treat type 2 diabetes

A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery. The report illustrates the findings of the first international consensus conference -- Diabetes Surgery Summit (DSS) -- where an international group of more than 50 scientific and medical experts agreed on a set of evidence-based guidelines and definitions that are meant to guide the use and study of gastrointestinal surgery to treat type 2 diabetes. The document is considered to be the foundation of diabetes surgery as a medical discipline of its own.

24 Nov 2009

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Researchers from the University of California, San Diego recently offered the sharpest-yet picture of how core biochemical pathways in skeletal muscle cells and fat cells are altered in people who suffer from insulin resistance-a primary defect in type 2 diabetes and obesity. Taking a systems biology approach, the bioengineers and medical researchers also determined how a common class of drugs for treating insulin resistance-TZDs-alter these same core pathways.

24 Nov 2009

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

European Phase III clinical trial of budesonide MMX completes patient enrollment

Research finds change in the outlook of people with type 2 diabetes and heart disease

Roche announces results of phase III taspoglutide study in diabetes patients

FDA approves Schering-Plough's New Drug Application for ZEGERID OTC capsules

DiaMedica to acquire all issued and outstanding shares of Sanomune

LeapFrog Investments announces ZAR 50 million investment in AllLife

D-ATLAS to map the prevalence and costs associated with type 2 diabetes launched

Type 1 diabetes youth have abnormal insulin resistance that may increase risk of cardiovascular disease

Women with gestational glucose intolerance at risk of metabolic syndrome

Drinking sugar-sweetened cola a week prior to pregnancy elevates diabetes during pregnancy

European Commission approves MICARDIS medication for CV protection

Researchers predict diabetes cases to double and cost to triple in the next 25 years

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

Experts say vitamin D assists body's immune system to fight against H1N1

Aetna Better Health teams up with Hartford student to highlight the importance of diabetes and health literacy

Human Genome Sciences submits BLA for ZALBIN

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

DSS sets evidence-based guidelines and definitions to treat type 2 diabetes

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in